Human tumor xenografts in a nude rat model are used to conduct in vivo efficacy evaluation of potential cancer therapies. Our broad range of tumor lines ensures a wide variety of testing alternatives.

Our xenograft portfolio is evaluated on a regular basis for response to standards of care and this data is available for designing combination studies.

Our scientific staff can assist in selecting the most appropriate model for your agent. Complete profiling of agents can be carried out in a variety of tumor types or in combination with the appropriate clinical agent. These models are offered as a second species for clients preparing for their IND filing.

Specially requested lines can be developed if a model of interest is not among those listed below:

Tumor Type Cell Line
Brain U87MG
Breast MDA-MB-231
Colon HCT116, HT29
Epidermoid A431
Leukemia MV4-11, RS4;11, THP-1
Lung H460
Melanoma A2058, A375
Ovarian A2780
Pancreatic MiaPaCa-2
Prostate PC3

Efficacy evaluation can be combined with:

  • Hematology (CBC/Diff) analysis
  • Pharmacokinetic or bioavailability sampling and analysis
  • Histopathology or tissue sampling
  • Biomarker screening, sampling or evaluation